Literature DB >> 3538996

Pericentric inversions in man. A French collaborative study. Groupe de Cytogénéticiens Français.

.   

Abstract

Pericentric inversions ascertained by the majority of French cytogenetics laboratories are collected and analysed. The whole sample is composed of 305 independent cases, most of which unpublished previously. inv(2)(p1200q14.100) = 87 probands, inv(5)(p1400q1400) = 22 probands, inv(10)(p11.22q21.109) = 17 probands, and inv(10)(p1209q11.109): 12 probands are the most recurrent. The risk of aneusomie de recombinaison varies from .00 to .10 in the progeny of inversion carriers, depending on the location of the breakpoints. The risk of other chromosome imbalances may be increased by a factor of 3, and that of abortions by a factor of 2. A reduction of fertility is likely to exist in male carriers, especially when large chromosomes are involved. In most instances, the apparent preferential segregation of the inverted chromosome may be due to ascertainment biases, but such segregations may exist for some recurrent inversions. Endogany may also explain recurrence, such as that of inv(2)(p12q14.100) which is observed mostly in the Jewish community originating from Spain before inquisition time and from North Africa.

Entities:  

Mesh:

Year:  1986        PMID: 3538996

Source DB:  PubMed          Journal:  Ann Genet        ISSN: 0003-3995


  18 in total

Review 1.  The critical region on the human Xq.

Authors:  E Therman; R Laxova; B Susman
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

Review 2.  Sperm chromosome analysis of a man heterozygous for a pericentric inversion of chromosome 20.

Authors:  J Jenderny; J Gebauer; G Röhrborn; A Rüger
Journal:  Hum Genet       Date:  1992-04       Impact factor: 4.132

3.  The variant inv(2)(p11.2q13) is a genuinely recurrent rearrangement but displays some breakpoint heterogeneity.

Authors:  Ina Fickelscher; Thomas Liehr; Kathryn Watts; Victoria Bryant; John C K Barber; Simone Heidemann; Reiner Siebert; Jens Michael Hertz; Zeynep Tumer; N Simon Thomas
Journal:  Am J Hum Genet       Date:  2007-08-28       Impact factor: 11.025

4.  De novo inv(17)(p11.2q21.3) in an intellectually disabled girl: appraisal of 21 inv(17) constitutional instances.

Authors:  Miriam Partida-Pérez; María G Domínguez; Vivian Alejandra Neira; Luis E Figuera; Horacio Rivera
Journal:  J Genet       Date:  2012-08       Impact factor: 1.166

5.  Pericentric inversion of chromosome 9 in infertile men.

Authors:  I Sasagawa; M Ishigooka; Y Kubota; M Tomaru; T Hashimoto; T Nakada
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

6.  Breakpoint cloning and haplotype analysis indicate a single origin of the common Inv(10)(p11.2q21.2) mutation among northern Europeans.

Authors:  Mette Gilling; Jörn S Dullinger; Stefan Gesk; Simone Metzke-Heidemann; Reiner Siebert; Thomas Meyer; Karen Brondum-Nielsen; Niels Tommerup; Hans-Hilger Ropers; Zeynep Tümer; Vera M Kalscheuer; N Simon Thomas
Journal:  Am J Hum Genet       Date:  2006-03-17       Impact factor: 11.025

7.  Fragile sites and breakpoints in constitutional rearrangements and in human sperm chromosomes.

Authors:  C Fuster; R Miró; C Templado; L Barrios; V Moreno; J Egozcue
Journal:  Hum Genet       Date:  1989-07       Impact factor: 4.132

8.  Correlation between chromosomal breakpoint positions and synaptic behaviour in human males heterozygous for a pericentric inversion.

Authors:  A de Perdigo; O Gabriel-Robez; Y Rumpler
Journal:  Hum Genet       Date:  1989-10       Impact factor: 4.132

9.  Studies of male and female meiosis in inv(4)(p1.4;q2.3) pig carriers.

Authors:  Katia Massip; Martine Yerle; Yvon Billon; Stéphane Ferchaud; Nathalie Bonnet; Anne Calgaro; Nicolas Mary; Anne-Marie Dudez; Céline Sentenac; Christophe Plard; Alain Ducos; Alain Pinton
Journal:  Chromosome Res       Date:  2010-12-02       Impact factor: 5.239

10.  Homozygosity for inversion (2)(p12q14).

Authors:  Z Gelman-Kohan; J Rosensaft; R N Ben-Cohen; J Chemke
Journal:  Hum Genet       Date:  1993-10       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.